Related Experiment Video

Updated: Dec 26, 2025

Author Spotlight: Exploring Corneal Innate Immunity and Delayed Wound Healing in Diabetic Patients
03:57

Author Spotlight: Exploring Corneal Innate Immunity and Delayed Wound Healing in Diabetic Patients

Published on: January 10, 2025

20.2K

Fingolimod-associated macular edema controlled with nepafenac non-steroidal anti-inflammatory opthalmologic

Rachel Husmann1, John B Davies2, Malik Ghannam3

  • 11University of Minnesota, Minneapolis, MN USA.

Clinical and Molecular Allergy : CMA
|March 20, 2020
PubMed
Abstract

Insights

Fingolimod-associated macular edema (FAME), a complication of multiple sclerosis treatment, can be managed with nonsteroidal anti-inflammatory eye drops. This approach allows patients to continue fingolimod therapy with close monitoring.

Area of Science:

  • Ophthalmology
  • Neurology
  • Pharmacology

Background:

  • Fingolimod is a key treatment for relapsing-remitting multiple sclerosis (RRMS).
  • Fingolimod-associated macular edema (FAME) is a rare but known complication, affecting 0.4% of patients.
  • Current guidelines recommend discontinuing fingolimod to manage FAME.

Observation:

  • A case study involved a 38-year-old female patient with RRMS treated with fingolimod who developed FAME.
  • The patient's FAME was successfully treated using nonsteroidal anti-inflammatory (NSAID) eye drops.

Findings:

  • FAME can be effectively managed with NSAID eye drops.
  • Continuation of fingolimod therapy is possible during FAME treatment with NSAID eye drops.

Implications:

  • This suggests a potential alternative management strategy for FAME, avoiding fingolimod cessation.
  • Further research and case studies are warranted to validate this treatment approach for FAME.
  • This could improve treatment adherence and outcomes for RRMS patients experiencing FAME.
Keywords:
FingolimodMacular edemaMultiple sclerosisNonsteroidal anti-inflammatory eye dropsRetina

More Related Videos

Use of Rabbit Eyes in Pharmacokinetic Studies of Intraocular Drugs10:02

Use of Rabbit Eyes in Pharmacokinetic Studies of Intraocular Drugs

Published on: July 23, 2016

33.1K
Electroporation-Based Genetic Modification of Primary Human Pigment Epithelial Cells Using the Sleeping Beauty Transposon System07:04

Electroporation-Based Genetic Modification of Primary Human Pigment Epithelial Cells Using the Sleeping Beauty Transposon System

Published on: February 4, 2021

2.3K

Related Concept Videos

Open Angle Glaucoma: Treatment01:27

Open Angle Glaucoma: Treatment

In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
891
Angle Closure Glaucoma: Treatment01:28

Angle Closure Glaucoma: Treatment

Angle-closure glaucoma, or closed-angle glaucoma, is an eye condition where the iris bulges out and blocks the iridocorneal angle, resulting in a buildup of aqueous humor and increased intraocular pressure. Immediate medical attention is necessary due to the sudden onset of symptoms. The treatment for angle-closure glaucoma includes short-term and long-term approaches. Short-term treatment involves using eye drops like pilocarpine to lower intraocular pressure by increasing aqueous humor...
1.0K
Glaucoma: Overview01:25

Glaucoma: Overview

Glaucoma is an eye condition characterized by increased intraocular pressure that damages the retina and optic nerve, leading to irreversible blindness if left untreated. The human eye has various components, including the cornea, iris, pupil, lens, and optic nerve. Aqueous humor is secreted by the epithelium of the ciliary body in the posterior chamber and flows through the trabecular meshwork and canal of Schlemm, maintaining normal intraocular pressure. The trabecular meshwork and the canal...
1.1K